Bortezomib-induced cutaneous lesions in multiple myeloma patients: A case report
| Autor: | M Sáez-Rodríguez, Marina Rodríguez-Martín, A. Noda-Cabrera, M García-Bustínduy, Antonio Martín-Herrera |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2008 |
| Předmět: |
Melphalan
Vincristine Cyclophosphamide Bortezomib business.industry medicine.medical_treatment Dermatology General Medicine Hematopoietic stem cell transplantation medicine.disease Peripheral neuropathy immune system diseases hemic and lymphatic diseases medicine Cancer research business Multiple myeloma Dexamethasone medicine.drug |
| Zdroj: | Rodríguez-Martín, M; Sáez-Rodríguez, M; García-Bustínduy, M; Martín-Herrera, A; & Noda-Cabrera, A. (2008). Bortezomib-induced cutaneous lesions in multiple myeloma patients: A case report. Dermatology Online Journal, 14(11). Retrieved from: http://www.escholarship.org/uc/item/0cv3t3f4 |
| Popis: | Proteasome inhibitors are emerging as a promising class of anti-cancer therapeutic agents. Bortezomib (PS341) is the first proteosome inhibitor with clinical significance. It acts by blocking vital functions of tumoral cells in myeloma, inducing apoptosis. Its toxicity is usually manageable. Gastrointestinal symptoms, peripheral neuropathy, neuropathic pain and thrombocytopenia are described as the most common side effects. We report on a case of cutaneous lesions induced by bortezomib in a patient with relapsed multiple myeloma (MM). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|